Us2.ai receives FDA clearance for Us2.v2,transforming…

Syntonix Pharmaceuticals, Inc. and Boehringer Ingelheim announced today that they have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix’ SynFusionTM and TransceptorTM technologies. Under the terms of the agreement, Syntonix will receive an upfront fee and research support. Boehringer Ingelheim has the option to develop and commercialize the peptide candidates. Syntonix will receive milestone and royalty payments on any products developed and commercialized under the agreement.